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Adjuvant management of locally advanced oral squamous cell carcinoma – real 
world challenges and opportunities.  
 
Authors: 
Dr R.C. Brooker FRCR MRCP MBChB (a, c) 
Doctoral Research Fellow / ST7 Clinical Oncology 
 
Mr A. Hobkirk FDSRCS FRCS(OMFS) FCMI (b) 
Consultant Oral and Maxillofacial Surgeon 
 
Ms H. Cashman BChD MFDS (RCS Ed) (b) 
Dental Core Trainee 
 
Mr T. Sato MBBS MSc BDS MRCS FFD RCSI (b) 
Specialty Registrar, Oral and Maxillofacial Surgery 
 
Mr D. Broderick FFD (OSOM) FRCS (b) 
ST7 Oral and Maxillofacial Surgery 
 
Dr H. Wong PhD(a) 
Quality Manager (Audit & Statistics) 
 
Mr P. Kyzas PhD FRCS (OMFS) (d) 
Consultant OMFS Head & Neck Surgeon 
 
Dr A. Haridass FRCR MRCP MSc MBBS (a) 
Consultant Clinical Oncologist 
 
Dr J. J. Sacco PhD MRCP MSc MBChB (a, c) 
Clinical Senior Lecturer and Honorary Consultant in Medical Oncology 
 










Clinical Senior Lecturer in Head & Neck Surgery 
 







b) Head and Neck Unit 
Aintree University Hospital NHS Foundation Trust 






c) Liverpool Head & Neck Centre 
Department of Molecular and Clinical Cancer Medicine  
University of Liverpool Cancer Research Centre,  





d) North Manchester General Hospital 







Dr R. C. Brooker  
Liverpool Head & Neck Centre 
Department of Molecular and Clinical Cancer Medicine  
University of Liverpool Cancer Research Centre,  





















Background:   Patients with locally advanced oral squamous cell cancer (LAOSCC) are treated with 
adjuvant radiotherapy (RT) or chemoradiotherapy (CRT), following surgical ablation. This depends on 
pathological risk factors and aims to reduce local recurrence risk and improve survival.  Delivery of 
these aggressive treatments is however challenging particularly following major surgery.   
Aim:  Describe real world delivery of multimodality treatment in LAOSCC, in a UK population with 
high levels of disease incidence and low socioeconomic status, informing adaptations necessary to 
deliver gold standard therapy. 
Method:  Patients with LAOSCC (T1-4 N1-3/T3-4 N0) treated between October 2014–October 2016 
with a minimum 24 months follow-up were included.  Patients were identified using Somerset 
Cancer Register and data collected through retrospective case note review.  Approval was obtained 
from relevant NHS institution audit departments and data analysed using IBM SPSS Statistics 24.  
Results:  Analysis included 129 patients with 82% having initial performance status (PS) of 0-1.  The 
most frequent PS change was 1 point drop (46%).   20 out of 93 patients eligible (22%) underwent 
                                                          
1 Abbreviations: 
SCCHN – Squamous Cell Carcinoma of the Head and Neck 
CRT/RT – Chemoradiotherapy / Radiotherapy 
cK – Cohen’s Kappa Statistic 
PS – WHO performance status 
LA - Locally advanced 











adjuvant CRT.    40% (37) began adjuvant CRT/RT within 42 days and 85% (79) within 56 days.  Delay 
in initiating adjuvant therapy was associated with higher rates of complication and longer post-
operative hospital stay.  Concordance between imaging and pathological nodal staging was poor (cK 
0.223). 
Conclusion:  PS frequently declines after complex surgical procedures and long post-operative 
recovery periods leading to difficulties providing adjuvant treatments within the national guidance 
of 42 days.  Frequent deviation from planned adjuvant therapies highlights the need for improved 
treatment strategies. 
Key Words:  Oral cancer, squamous cell carcinoma, chemoradiotherapy, maxillofacial surgery, 
adjuvant.   
Introduction/Background 
Treatment strategies for locally advanced oral squamous cell carcinoma (LAOSCC) typically employ 
multimodality therapy (surgery and adjuvant (chemo) radiotherapy (CRT/RT)) to eradicate primary 
disease and mitigate the risk of future recurrence.  The standard of care for fit patients under 70 
years with high-risk disease (extracapsular extension (ECS) in involved nodes and/or involved surgical 
margins) is cisplatin chemotherapy concurrently with RT [1, 2]. Despite these intensive regimes, long-
term survival remains poor [3]. These adjuvant treatment regimes can be highly toxic, and are 
delivered to a population with multiple comorbidities and frequently, high levels of smoking/alcohol 
excess. Despite their recommendation within national guidelines, the reality is that delivery of these 
treatments to patients that have undergone life-changing reconstructive maxillofacial surgery is 
challenging [4].   
Reliable pre-operative staging is extremely valuable when embarking upon complex therapeutic 
pathways.   In order to adequately stage patients before surgical resection imaging (MRI, CT and/or 










interpretation of findings and inter-observer variability.  Maximising the accuracy of pre-operative 
staging is not only beneficial to patients in improving their journey and providing realistic 
expectations of their treatment path but also to ensure a streamlined service with early recruitment 
to clinical trials if available.   
Delays to initiating adjuvant RT following radical surgery have a negative impact upon survival [6, 7].  A 
recent large observational cohort study conducted by Harris et al confirmed the survival advantage 
of shorter intervals between surgery and adjuvant RT. They reported an improvement in median OS 
of 4.1 years (95%CI 3.4-4.7) for 25,216 SCCHN patients within their cohort who had an interval of 
under 42 days compared to those over 50 days [8]. Given these findings, the British Association of 
Head and Neck Oncologists (BAHNO) and the National Comprehensive Cancer Network (NCCN) 
advocate initiating adjuvant treatment within 42 days in all sub-sites to minimise the impact of 
treatment delays upon outcomes and clearly this relies upon a coordinated service [9, 10].   Assessing 
the deliverability of this target will inform whether the particular complexities of oral and 
maxillofacial surgery and subsequent recovery periods need to be taken into account in expected 
treatment times.   
We sought to review the current practice within two large tertiary referral Head & Neck units against 
the recommended adjuvant treatment path outlined within the United Kingdom National 
Multidisciplinary Guidelines, along with determining the accuracy of pre-operative staging [4].  In 
parallel, we assessed the frequency with which patients are currently able to complete the course of 
standard adjuvant therapy and the ability to commence adjuvant treatment within six weeks of 
surgery (as per BAHNO/NCCN standards) [9, 10].  
Objectives and standards 
 Concordance of clinical/radiological staging with pathological staging. 
 Temporal changes in performance status following surgical ablation/reconstruction and impact 









 Proportion of patients suitable for adjuvant CRT compared to those who received CRT and 
reasons for changing treatment path. 
 Proportion of patients who to commenced adjuvant RT within six weeks [9, 10].  
Methods  
Approval for retrospective data collection and audit was obtained from Aintree University 
Hospital/The Clatterbridge Cancer Centre and North Manchester General Hospital audit 
departments. Patients with LAOSCC based on the seventh edition of the American Joint Committee 
on Cancer Staging (i.e. T1-4 N1-3 or any T3-T4 N0) treated between October 2014 – October 2016 
with radical surgery were identified via Somerset Cancer Register [11, 12].  All cases undergoing radical 
surgery were planned for adjuvant RT/CRT depending on established pathological risk factors. 
Patient outcomes were obtained through retrospective case note review; of note performance 
status (PS) was documented at two different time points with evaluations made by different 
assessors. Detailed tumour resection pathology reports, imaging reports and initial clinical 
examination documentation were obtained and surgical length of stay with staging information 
recorded.  Surgical complications were graded using the Clavien-Dindo classification system [13].  RT 
was delivered using Volumetric Modulated Arc Therapy (VMAT) with 66gy in 33 fractions prescribed 
with concurrent cisplatin either 100 mg/m2 every 21 days for 3 cycles or 40mg/m2 weekly.  If 
cisplatin was contraindicated substitution with carboplatin or cetuximab could be considered.  The 
adjuvant RT regimes were 40-65Gy in 20-32 fractions depending on individual treating clinical 
oncologist preference and pathological risk factors.   
Kaplan-Meier survival curves were used to analyse overall survival (OS) and progression free survival 











A total of 158 patients were initially identified; however 29 patients were subsequently excluded 
from analysis (primary site other than the oral cavity and/or histological type other than SCC).    Of 
these remaining 129 patients with LAOSCC there were 55 females and 74 males with an average age 
of 64 years (39-86 years).  53% were current cigarette smokers and 73% current consumers of 
alcohol (Table 1).  
Median OS and DFS for the whole population were 38 months (95%CI 18.8-57.2) and 34 months 
(95%CI 21.9-46.1) respectively (Figure 1).  The three-year OS rate was 44.8% which is in keeping with 
the three-year OS rate of 45-47% quoted by the NCRAS [3].  
A total of 93 (72.1%) patients received post-operative adjuvant treatment.  PS was assessed prior to 
surgical resection and again prior to adjuvant treatment planning.  At presentation the majority of 
patients (72/129, 55.8%) were PS 0 (Table 1). At post-operative assessment only 12 patients were 
assessed as PS 0 with 89 patients now PS 1 or 2; the most frequent PS drop was 1 point (46%).  8 
(6.2%) patients had an improvement in PS following surgical resection; the majority (8) having a rise 
of 1 point.    
Following standard protocols for adjuvant treatment, 93 patients would have been recommended 
for CRT, (involved margin <1mm and ECS).  Of this group, only 20 received CRT; due to deterioration 
in PS post-surgery (43%), poor PS at first assessment (20%), post-operative complications (8%), early 
recurrence (7%), comorbidities (3%), previous head and neck RT (3%), patient declined (4%) and no 
reason documented (13%).   Of note there were 30 (33%) aged over 70 years with high risk 
pathological factors, none of whom received chemotherapy in addition to their adjuvant RT.  It was 
not specified within clinic notes if age was taken into account when deciding whether to offer CRT 
however it was evident that the majority of these patients had PS≥2 (83%).  Of the 20 patients who 
underwent CRT, all received cisplatin chemotherapy; five were planned to have weekly 40mg/m2 
infusions and fifteen 100mg/m2 every 21 days.  Six completed the planned course of three cycles of 










to chemotherapy toxicities.  Median OS for patients with high risk pathological features were 54 
months in those receiving CRT (16.6-91.4), 23 months in those receiving adjuvant RT (95%CI 14.6-
31.4) and 9 months in those receiving no adjuvant treatment (95%CI 5.1-12.9) (Figure 2).    
73 patients underwent adjuvant RT alone.  Despite the recommendation for post-operative RT based 
on pathological features 36 patients received no adjuvant treatment.  Reasons for omitting adjuvant 
RT were post-operative deterioration in PS (36%), prior head and neck RT (14%), recurrence prior to 
commencement of RT (8%), patient choice (14%), death prior to treatment (3%), and unknown 
(25%).  Six individuals received palliative RT.  
The modal time to commence adjuvant treatment was 42 days (max 116, min 28); 37 patients (40%) 
began adjuvant CRT/RT within 42 days and 85% (79) began within 56 days.  There were 12 patients 
who took ≥56  days  to begin adjuvant treatment and the reasons for this were recovery from post-
operative complications (46%), administration error / did not attend when requested (8%), patient 
moved to different area (8%) and unknown (38%).  A delay in initiating adjuvant therapy was 
associated with longer recovery times and higher complication rate.  For those who did not initiate 
adjuvant therapy within 42 days the median length of hospital stay post-surgery was 16 days along 
with grade IIIa-V Clavien-Dindo complication rate of 30% (16); compared to 11 days and 
complication rate of 8% (3) in the group of patients who did meet the 42 day standard (Figure 3).   
There was concordance between clinical and pathological tumour staging in 72% of cases (cK 0.551), 
assessment of nodal staging was less reliable with 49% concordance (cK 0.282). When evaluating 
radiological tumour staging there was 65% agreement with pathological tumour staging (cK 0.462).  
Radiological nodal staging showed a 44% concordance with 35% of cases upstaged and 20% down-
staged following pathology reporting (cK 0.223).  5 individuals could not be compared as their neck 











This research highlights the significant challenges evident in the delivery of “ideal” therapeutic 
regimes to patients with locally advanced oral cavity cancer.  In particular, these results provide 
evidence of a significant deterioration in patients’ PS following surgical treatment for this disease, 
with 88 individuals (68%) experiencing a demonstrable a fall in PS. The drop in physical fitness is a 
product of their intensely complex surgical resection and reconstruction and patient co-morbidities.  
The intimate association and disruption to patients’ normal upper aerodigestive tract leads to 
prolonged recovery times, increased length of hospital stay and the subsequent, increased risk of 
post-operative complications [15].  Ultimately once patients have recovered from their surgical 
procedure, any delays within perioperative management bring the patient close to (or even outside) 
the recommended window for initiating adjuvant treatment.  Altered PS and the sequelae of 
treatment frequently render patients too unwell to consider concurrent cisplatin chemotherapy or 
RT alone even if they have pathological risk factors which would suggest treatment is indicated. 
Only 37 (40%) patients receiving adjuvant treatment did so within the national standard of 42 days.  
For those treated outside the national standard, 56% (30 patients) were still inpatients at 14 days 
following their operation (compared to 32%, (12 patients) in those treated within 42 days), and 
there was a higher rate of grade IIIa-V Clavien-Dindo complications (30% compared to 8%); 
reinforcing the above conclusions (figure 3).    It is evident that this timeline to commencement of 
adjuvant therapy is not achievable for all patients undergoing surgical procedures for SCCHN and 
does not take into account the varying surgical complexities across each sub-specialty nor the reality 
of treating patients with multiple (often undiagnosed) pathologies following a history of long term 
nicotine and alcohol dependence.    
Tri-modality therapy (surgery, chemotherapy and radiotherapy) is an intensive regime which has a 
dramatic effect upon quality of life [16].  This is reflected in the low proportion of patients completing 
a full course of adjuvant CRT without modification.  Our three year OS rate of 44% reinforces the 










the current ‘gold standard’ management shows how difficult this will be to achieve in our 
population.   Similarly the TITAN study highlighted patients with LA OSCC as a population difficult to 
escalate treatment due to advancing age and poor performance status.  This study had planned to 
provide induction cisplatin, 5-fluorouracil and docetaxel chemotherapy prior to ablative surgery for 
patients with resectable HPV negative SCCHN but could not progress from feasibility to phase III due 
to difficulties recruiting [16].  Clearly patients with LAOSCC require a nuanced approach to adjuvant 
treatment with appropriate intensification for those individuals who are fit but also less toxic 
adjuvant options (namely alternatives to cisplatin chemotherapy) for the majority of patients who 
have poorer PS and comorbidities.  Future clinical trials will consider the integration of new systemic 
anti-cancer therapies (i.e. immunotherapies) into the neo-adjuvant setting in order to maximise 
upon the window of opportunity to treat individuals before their physical fitness deteriorates 
following complex surgical procedures.    Clearly careful patient selection and accurate pre-
treatment staging is essential to recruit effectively to any study that attempts to enrol at 
presentation.  This research highlights the significant challenges in accurately assessing tumour stage 
in the preoperative setting by clinical and radiological means alone (concordance between 
radiological nodal status and definitive pathology was poor (cK 0.223), and hence, the constraints 
this places on adjuvant treatment planning and will require a recruitment strategy capable of 
overcoming, or at worst accommodating, the paradox between inaccurate clinic staging and delayed 
(post-operative) definitive staging. 
We recognise some limitations inherent in this survey. The retrospective nature of the data 
collection meant that there was reliance upon case note documentation; however records were 
cross-referenced across two NHS trusts to verify data. Review of notes at both surgical and oncology 
NHS trust sites allowed inter-observer variability in scoring PS and noting treatment toxicities. 
Despite this, all patients were discussed at multidisciplinary team meetings where PS is reviewed 
routinely thus minimising this variability.  Inclusion of consecutive cases, managed in the respective 









papillomavirus (HPV) status was not deemed relevant given the low prevalence in oral cavity cancer 
and, in addition, routine HPV testing is not currently recommended in non-oropharyngeal sites [18, 19, 
20].    
Conclusions 
This study has brought to the forefront the reality of treating patients in the true population with 
multimodality therapies.  Discordance in radiological and pathological staging along with 
deterioration in performance status as a consequence of treatment intensity necessitates 
management plans and procedures capable of adaptation to ensure individuals receive the 
appropriate adjuvant regimes.  Future clinical trials should be designed to focus upon the neo-
adjuvant treatment window and upon developing alternative, less toxic adjuvant regimes for 
patients with high risk LAOSCC in order to allow intensification of therapy thus improved outcomes.   
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Table 1: Patient and treatment characteristics 
PATIENT CHARACTERISTICS FREQUENCY PERCENT MEAN MIN/MAX 
Age     
 <50 13 10.1 64 39-86 
 51-60 32 24.8 
 61-70 42 32.6 
 71-80 32 24.8 
 >81 10 7.8 
 
Male 74 57.4   
Female 55 42.6 
 
  
Non Smoker 34 26.4   
Ex-Smoker 25 19.4   
Current Smoker 69 53.5   
Unknown  1 0.8 
 
  
Nil Alcohol 32 24.8   
Current Alcohol 95 73.6   
Unknown alcohol  2 1.6   
     
PS at initial assessment     
PS 0  72 55.8   
PS 1 34 26.4   
PS 2 14 10.9   








PS at adjuvant assessment     
PS 0  12 9.3   
PS 1 46 35.6   
PS 2 43 33.3   
PS 3 16 12.4   
PS 4 1 0.8   
PS 5 1 0.8   
Unknown 10 7.8.0   
     
Time to RT/CRT     
20-35 days 16 17.2   








43-49 days 26 28.0 
50-56 days 16 17.2 
≥57 days 12 12.9 
Unknown 2 2.2 
   
Adjuvant treatment   
Chemoradiotherapy 20 15.5   
Radiotherapy 73 55.8   
None 36 28.7   



















95% Confidence Interval Estimate Std. 
Error 









36.316 2.199 32.007 40.626 38.000 9.795 18.802 57.198 
 
































Means and Medians for Survival Time 
Treatment Meana Median 
Estimate Std. 
Error 
95% Confidence Interval Estimate Std. 
Error 









None 13.025 2.984 7.176 18.874 9.000 2.012 5.056 12.944 
RT 30.885 2.933 25.137 36.633 23.000 4.274 14.623 31.377 
CRT 38.982 4.958 29.265 48.700 54.000 19.074 16.615 91.385 
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Table 2: Tumour characteristics 
TUMOUR CHARACTERISTICS FREQUENCY PERCENTAGE 
Margin    
Involved (<1mm) 56 43.4 
1-5mm 49 38.0 
>5mm 24 18.6 
   
Nodal ECS   
ECS + 58 45.0 
ECS - 68 52.7 
Not assessed 3 2.3 
   
Clinical Staging   
T1 6 6.7 
T2 41 31.5 
T3 8 6.7 
T4 74 55 
   
N0 84 65.1 
N1 22 17.1 
N2a 3 2.3 
N2b 12 9.3 
N2c 6 4.7 
Nx 2 1.6 
   
Radiological Staging   
T1 8 6.2 
T2 22 17.1 
T3 11 8.5 
T4 75 58.1 
Not assessed 3 2.3 
   
N0 62 48.1 
N1 22 17.1 
N2a 1 0.8 
N2b 27 20.9 
N2c 10 7.8 
Nx 7 5.4 
   
Pathological Staging   
T1 6 4.7 
T2 38 29.5 
T3 24 18.6 
T4 61 47.3 
   
N0 39 30.2 
N1 39 30.2 
N2a 0 0 
N2b 36 27.9 
N2c 11 8.5 











Figure 4: Concordance between pathological and radiological staging 
 
Radiological T stage (Tr) Pathological T stage (Tp)  
 1 2 3 4 Total 
1 1 4 2 2 9 
2 5 21 4 2 32 
3 0 5 6 0 11 
4 0 8 11 57 76 
X 0 0 1 0 1 
Total 6 38 24 61 129 
 
Tr vs Tp N % 
Pathologically downstaged 30 23% 
Same 85 65% 
Pathologically upstaged 14 11% 
Total 129 100.0% 
 
 
Tr vs Tp Value Asympt. Stand. 
Errora 





0.462 0.057 7.923 .000 




Pathological N stage (Np)  
 0 1 2a 2b 2c Total 
0 29 14 1 14 5 63 
1 3 10 0 7 2 22 
2a 0 0 0 1 0 1 
2b 5 10 0 12 0 27 
2c 2 4 0 1 4 11 
Total 39 38 1 35 11 124 
 
Nr vs Np N % 
Pathologically downstaged 25 20% 
Same 55 44% 
Pathologically upstaged 44 35% 
Total 124 100.0% 











Nr vs Np Value Asympt. Stand. 
Errora 





0.223 0.058 4.270 .000 
N  Valid Cases 124 
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